Key clinical point: Levels of metabolites could help clinicians deliver more targeted treatment earlier in patients’ disease course.
Major finding: Researchers assessing levels of metabolites such as phospholipids were able to identify patients as having schizophrenia or bipolar disorder, or as healthy controls, 87.1% of the time.
Study details: Study of 55 patients with schizophrenia or bipolar disorder and 30 healthy controls.
Disclosures: Dr. Joaquim reported no relevant disclosures.
REPORTING FROM SIRS 2019